Jpn J Pharmacol data (2001”N12ŒŽ31“ϊŒ»έƒQƒ“ƒUƒC)
@ “ΰƒEƒ` ŠCŠOƒJƒCƒKƒC
˜_•ΆRΈŒ‹‰Κ@@@@@@@ “Še˜_•Ά‚Μ•ͺ–μ (œ Review)@@@@@
@ 1999 2000 2001 @ @ 1999 2000 2001 @
Žσ— 180 21 186 25 182 26 @ 1.Ά—Šˆ«•¨ŽΏ 5 2 7 3 7 @ @
Reject 24 7 24 12 41 16 @ ‚Q.Žσ—e‘́Eƒ`ƒƒƒlƒ‹E—A‘—Œn 12 1 14 1 20 3 @
Žζ‰Ί‚° 24 4 12 2 19 4 @ ‚R.Χ–E“ΰξ•ρ“`’B 4 @ 6 1 2 @ @
‡Œv 228 32 222 39 242 46 Œ ‚S.Ά‰»Šw–ς— 19 6 14 5 16 4 @
Reject—¦(Šά.Žζ‰Ί‚°) 21.1 34.4 16.2 35.9 24.8 43.5 % ‚T.––½_Œo–ς— 6 @ 9 1 10 1 @
@@@@ ‚U.SŒŒŠΗ–ς— 42 5 40 5 38 3 @
‚V.’†•_Œo–ς— 33 4 44 11 36 11 @
“ŠeŒ” ‚W.ŒΔ‹zŠν–ς— 8 1 8 1 6 1 @
@ 1999 2000 2001 @ ‚X.t–ς— 5 @ 12 1 9 @ @
Full Paper 145 24 155 32 146 27 @ ‚P‚ODΑ‰»Šν–ς— 26 1 16 4 17 3 @
Short Commun. 51 1 64 9 54 7 @ ‚P‚PD•½ŠŠ‹Ψ–ς— 6 1 13 3 6 @ @
Rapid Commun. 1 0 8 0 3 0 @ ‚P‚QDœEŽ•‰Θ–ς— 7 @ 6 @ 7 @ @
Review 22 6 24 10 35 9 @ ‚P‚RD“ΰ•ͺ”ε–ς— 3 1 7 @ 6 2 @
Review “ΰ–σƒEƒ`ƒƒP [Invite R] 22 6 17 7 16 4 @ ‚P‚SD—Տ°–ς— 1 @ 2 2 4 @ @
@@[“Še] ˆκ”Κ   0 0 1 1 4 2 @ ‚P‚TD–Ζ‰u–ς—E‰ŠΗ 10 1 20 1 14 3 @
@@[“ŠeƒgƒEƒRƒE] F Mini R 0 0 6 2 14 3 @ ‚P‚UD‰»Šw—Γ–@ 2 1 4 1 1 1 @
@@[“ŠeƒgƒEƒRƒE] New Drug 0 0 0 0 1 0 @ ‚P‚VD“Ε‰ΘŠw 8 1 5 1 4 2 @
‡Œv 219 31 251 51 238 43 Œ ‡Œv 197 25 227 41 203 34 Œ
Invite RFInvite Review, F Mini R: Forum Minireview @ @ @ @ @ @ @ @
@ 1998 1999 2000 @
Impact Factor 1.533 1.21 1.317 @